Targeting CD137 may also enhance the efficacy of antibody-dependent cell-mediated cytotoxicity (ADCC) dependent mAb treatment because of the activation mechanism of the NK cellsUrelumab and rituximab combination treatment was assessed in patients with B cell lymphoma. Here, TNFRSF9 is linked to B-cell non-Hodgkin lymphoma.